Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Says Q4 Revenues Will Be About $3M Less Than Forecasted

NEW YORK, Jan. 2 (GenomeWeb News) - Ciphergen Biosystems announced today that its fourth quarter revenues will fall short of prior forecasts.


The company said its revenues for the quarter will be in the range of $15.0 to $15.5 million, as compared to prior expectations of about $19 million. Total revenue for the year is slated to come in at $58.5 million, a 50 percent year-over-year increase, according to Ciphergen.


The company attributed the anticipated revenue shortfall to fewer than expected placements of its ProteinChip systems in the US.


"A significant number of specific orders that we were anticipating near the end of the quarter did not materialize, although many of these we expect to carry forward to the first quarter," William Rich, Ciphergen's CEO, said in a statement. "We attribute the delays in orders to several factors, of which the most significant was increased indirect competition from centralized core proteomics facilities, as many such labs are attempting to provide biomarker discovery services to potential laboratory customers of ours."


Additionally, Rich said, "the entry of more direct competition resulted in a longer sales cycle at certain accounts, and we continued to experience delays from NIH and related funding sources."


The company said it plans to report its fourth quarter results on February 12, and that its revenue estimates could change before that time.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.